STTK (Shattuck Labs) חוב לטווח קצר להון

The market price visualization for Shattuck Labs, Inc. (STTK) demonstrates a debt-to-equity ratio of 0.00. The business relies on automated systems for the rapid analysis of anti-tumor proteins, eliminating manual labor. However, external conflicts are blocking raw material logistics and global testing. High clinical trial expenses create significant operating leverage, keeping returns at a low level.

The potential of Shattuck Labs, Inc. (STTK) in leukemia therapy requires significant investment prior to Phase 2 trials, making liquidity control critical. By analyzing the ratio of current liabilities to equity on GURU.Markets, an investor assesses the share of short-term borrowing within the equity structure; a decrease in this ratio minimizes default risk, confirming the company's financial stability while awaiting new licensing partnerships.